#LEUsm
LightNews LightNews
onclive.bsky.social
🇨🇳China's NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL, based on the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials.

Full details 💥: onclive.com/view/china-s...

#leusm #oncology
China's NMPA Approves Pirtobrutinib Across CLL | OncLive
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
onclive.com
September 28, 2026 at 6:54 PM
onclive.bsky.social
WATCH 👀: Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, of @petermaccc.bsky.social, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.

Full video ➡️: www.onclive.com/view/dr-ande...

#leusm #oncology #SOHO2026 @societyofhemonc.bsky.social
Dr Anderson on How to Approach Continuous vs Fixed-Duration Frontline Therapy in CLL | OncLive
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.
www.onclive.com
September 22, 2026 at 10:12 PM
onclive.bsky.social
Bexobrutideg drove responses across treatment lines in CLL/SLL, including in a subgroup of patients with treatment-naive disease. Dive into the #SOHO2026 data here #leusm #oncology www.onclive.com/view/bexobru...
Bexobrutideg Produces High Response Rates Across Treatment Lines in CLL/SLL | OncLive
Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.
www.onclive.com
September 15, 2026 at 7:14 PM
onclive.bsky.social
📈 Responses were shown in patients with R/R CLL who had received both a covalent BTK inhibitor and a BCL2 inhibitor, according to a pooled analysis of BRUIN trials.

Read more here ➡️: www.onclive.com/view/pirtobr...

#SOHO2026 #leusm #oncology @societyofhemonc.bsky.social
Pirtobrutinib Elicits Responses After Covalent BTK Inhibitor Failure in R/R CLL | OncLive
Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.
www.onclive.com
September 14, 2026 at 8:45 PM
onclive.bsky.social
🤔 Lower risks of TLS were shown for venetoclax-based regimens in patients with CLL compared with MCL, according to a real-world analysis.

Full details 📰: onclive.com/view/venetoc...

#leusm #lymsm #oncology #SOHO2026
@societyofhemonc.bsky.social
Venetoclax-Based Regimens Show Lower TLS Rates in CLL vs MCL | OncLive
Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.
onclive.com
September 14, 2026 at 5:17 PM
onclive.bsky.social
Phase 1 data show that dibotatug produced a 60% overall response rate with a favorable safety profile in large granular lymphocytic leukemia. @societyofhemonc.bsky.social #SOHO2026 #leusm #hematology

www.onclive.com/view/dibotat...
Dibotatug Is Safe and Yields Durable Responses in Large Granular Lymphocytic Leukemia | OncLive
Phase 1 data show that dibotatug produced a 60% overall response rate with a favorable safety profile in large granular lymphocytic leukemia.
www.onclive.com
September 11, 2026 at 10:01 PM
onclive.bsky.social
The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML. @societyofhemonc.bsky.social #SOHO2026 #leusm #hematology

www.onclive.com/view/ascimin...
Asciminib Maintains Superior MMR and Favorable Safety at 3 Years in Newly Diagnosed Ph+ CML | OncLive
The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML.
www.onclive.com
September 11, 2026 at 9:18 PM
onclive.bsky.social
Time-limited pirtobrutinib plus venetoclax and obinutuzumab produced high rates of U-MRD in CLL/SLL. #leusm #hematology

See our site for the full story from PIVOT-CLL, as presented by
@nitinjainmd.bsky.social at #SOHO2026! @societyofhemonc.bsky.social

www.onclive.com/view/time-li...
Time-Limited Pirtobrutinib-Based Triplet Yields High Rates of Undetectable MRD in First-Line CLL | OncLive
In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.
www.onclive.com
September 11, 2026 at 4:41 PM
onclive.bsky.social
ELVN-001 produced molecular responses in previously treated CP-CML according to updated data from the phase 1 ENABLE trial. @societyofhemonc.bsky.social #leusm #hematology

See our site for the full story, as presented at #SOHO2026! www.onclive.com/view/elvn-00...
ELVN-001 Produces Molecular Responses in Heavily Pretreated CP-CML | OncLive
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
www.onclive.com
September 10, 2026 at 9:20 PM
onclive.bsky.social
📈 The ACTIVE regimen yielded responses in heavily pretreated, relapsed or refractory NPM1-mutated AML, according to findings presented at #SOHO2026. @societyofhemonc.bsky.social #leusm #hematology

See the full story from the retrospective study on our site ➡️: www.onclive.com/view/active-...
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML | OncLive
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
www.onclive.com
September 10, 2026 at 7:52 PM
onclive.bsky.social
Adding revumenib to intensive chemotherapy led to high levels of response and MRD negativity in newly diagnosed AML harboring NPM1 mutations or KMT2A rearrangements #leusm #oncology

Check out the phase 1 data from #SOHO2026 www.onclive.com/view/revumen...
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML | OncLive
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
www.onclive.com
September 10, 2026 at 7:28 PM
matt-cortese.bsky.social
It’s an honor to be captain of Team @roswellpark.bsky.social and a Board of Trustee for @bloodcancerunited.bsky.social
I need your help raising $ for patients, families and critical research for blood cancer. These pennies still matter! #lymsm #mmsm #leusm #bmtsm
pages.lls.org/ltn/wcny/Buf...
Matthew's Light The Night Fundraiser
About Light The Night At Blood Cancer United’s Light The Night we gather as a community to celebrate, honor, and remember those touched by blood cancer. Companies, community partners, friends, familie...
pages.lls.org
September 10, 2026 at 12:10 PM
onclive.bsky.social
2️⃣ conferences at once! Get ready for #SOHO2026 in Houston and #WCLC26 in Seoul!
🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷
@societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology
September 9, 2026 at 8:17 PM
onclive.bsky.social
The addition of mipletamig to venetoclax/azacitidine drove clinical benefit in the frontline treatment of patients with AML harboring TP53 mutations #leusm #oncology

Dive into the phase 1b RAINIER data here: www.onclive.com/view/frontli...
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML | OncLive
Mipletamig plus venetoclax and azacitidine produced a CBR of 93% in induction-ineligible, TP53-mutated acute myeloid leukemia.
www.onclive.com
September 8, 2026 at 4:39 PM
onclive.bsky.social
An analysis showed that blood cancer treatment advances saved ~25.8 million life-years in the US between 1949 and 2024. #leusm #lymsm #hematology

E. Anders Kolb, MD, of @bloodcancerunited.bsky.social, shared insights during #BloodCancerAwarenessMonth and #WLD26: www.onclive.com/view/novel-a...
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments | OncLive
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
www.onclive.com
September 4, 2026 at 2:07 PM
eshaematology.bsky.social
📣 PRESENTING THE LEARNING OBJECTIVES OF #ESHAML2027
8th International Conference on AML "Molecular & Translational": Advances in Biology & Treatment
Oct. 4-6, 2027/Estoril, Portugal
Chairs: B. Löwenberg, H. Döhner, B. L. Ebert
For more information ➡ bit.ly/4t46boc
#ESHCONFERENCES #HAEMATOLOGY #LEUsm
September 2, 2026 at 9:19 AM
onclive.bsky.social
.@mayocliniccancer.bsky.social studies examined how clinicians and researchers can better identify, track, and measure the effects of blood cancer treatments on patients during and after treatment #lymsm #leusm #oncology www.onclive.com/view/mayo-cl...
Mayo Clinic Researcher Leads Lancet Commission Reports on Life During and After Blood Cancer Treatment | OncLive
Three new articles from The Lancet Hematology published today examine how clinicians and researchers can better identify, track and measure the effects of blood cancer treatments on patients during tr...
www.onclive.com
September 1, 2026 at 6:11 PM
eshaematology.bsky.social
📣 PROGRAMME HIGHLIGHT OF #ESHALL2027
3 SIMULTANEOUS MEET THE EXPERT SESSIONS
5th Translational Research Conference
ACUTE LYMPHOBLASTIC LEUKAEMIA
May 20-22, 2027/Malahide (Dublin), Ireland
Chairs: K. Bernt, N. Boissel, J.Cools, U. Wartiovaara-Kautto
More info ➡ bit.ly/49y6IaH
#ESHCONFERENCES #LEUsm
August 26, 2026 at 9:06 AM
onclive.bsky.social
MTBF conditioning before salvage allogeneic hematopoietic stem cell transplantation produced durable efficacy with manageable GVHD in in patients relapsed/refractory AML #leusm #oncology www.onclive.com/view/mbtf-be...
MBTF Before Allo-HSCT Produces Durable Efficacy and Manageable GVHD in R/R AML | OncLive
Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.
www.onclive.com
August 25, 2026 at 12:08 PM
onclive.bsky.social
Dordaviprone maintenance after HSCT was safe with low rates of grade ≥3 cytopenias in patients with AML and MDS #leusm #mpnsm #oncology www.onclive.com/view/posttra...
Posttransplant Dordaviprone Maintenance Is Safe With Low Cytopenia Rates in High-Risk AML and MDS | OncLive
Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.
www.onclive.com
August 18, 2026 at 3:10 PM
onclive.bsky.social
Lisa Niswander, MD, PhD, of Roswell Park Comprehensive Cancer Center, is investigating the combination of CAR T-cell therapy and targeted therapy for younger patients with leukemia #leusm #oncology

www.onclive.com/view/develop...
Developing Tomorrow’s Cancer Treatments Today: Meet a Pediatric Oncologist Working to Save Kids With Leukemia | OncLive
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
www.onclive.com
August 17, 2026 at 4:10 PM
onclive.bsky.social
Post hoc AMPLIFY data showed similar safety profiles for acalabrutinib plus venetoclax ± obinutuzumab among subgroups of younger and older patients with treatment-naive CLL #leusm #oncology www.onclive.com/view/fixed-d...
Fixed-Duration Acalabrutinib/Venetoclax Regimens Shows Similar Safety Across Age Groups in Treatment-Naive CLL | OncLive
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
www.onclive.com
August 12, 2026 at 7:11 PM
onclive.bsky.social
Jorge Cortes, MD, discusses the @FDA.gov approval of orally disintegrating nilotinib tablets for patients with chronic myeloid leukemia #leusm #hematology #oncology www.onclive.com/view/what-do...
What Does the FDA Approval of Orally Disintegrating Nilotinib Tablets Mean for CML Practice? | OncLive
Jorge Cortes, MD, discusses the FDA approval of orally disintegrating nilotinib tablets for patients with chronic myeloid leukemia.
www.onclive.com
August 12, 2026 at 1:26 PM
talhabadarmd.bsky.social
Exciting #DELPHINUS results: Dara + chemo achieved 83% ORR, with 75% proceeding to allo-HSCT and 24-month OS of 41% in R/R T-ALL.

As EA9213 co-chair, excited to see whether Dara can eradicate MRD and deepen remission in T-ALL. #TcellALL #Leusm

doi.org/10.1182/bloo...
Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study
Key PointsDaratumumab plus chemotherapy may effectively bridge children and young adults with relapsed/refractory T-cell ALL/LL to HSCT.No new safety conce
doi.org
August 8, 2026 at 10:40 PM
onclive.bsky.social
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas. @nitinjainmd.bsky.social @mdanderson.bsky.social #lymsm #leusm #hematology

www.onclive.com/view/docirbr...
Docirbrutinib Yields High Response Rates in MCL and CLL | OncLive
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
www.onclive.com
August 5, 2026 at 3:17 PM